Oncolys BioPharma Inc.
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
4588 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 港区虎ノ門４−１−２８虎ノ門タワーズオフィス１０階
- Website:
- https://www.oncolys.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Oncolys BioPharma Inc. is a biopharmaceutical company focused on developing breakthrough therapies and diagnostics for cancer and serious viral infections. The company's core strategy is centered on virology, specializing in the research, development, and commercialization of innovative drugs, particularly oncolytic viruses. Its pipeline addresses the full spectrum of cancer care, from early detection and prognostic tests to late-stage loco-regional and systemic treatments. A key product candidate is Telomelysin®, an oncolytic virus therapy. The company's business model involves advancing therapeutic candidates to early clinical proof-of-concept for licensing, with a mission to provide effective treatments that address significant unmet medical needs for patients and physicians.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Oncolys BioPharma Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 07:32 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2025-08-08 07:31 |
Interim Report
半期報告書－第22期(2025/01/01－2025/12/31)
|
Japanese | 271.3 KB | |
| 2025-07-18 08:30 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 877.6 KB | |
| 2025-03-31 03:16 |
Regulatory News Service
臨時報告書
|
Japanese | 27.7 KB | |
| 2025-03-28 02:16 |
Regulatory News Service
内部統制報告書－第21期(2024/01/01－2024/12/31)
|
Japanese | 22.6 KB | |
| 2025-03-28 02:15 |
Annual Report
有価証券報告書－第21期(2024/01/01－2024/12/31)
|
Japanese | 1.2 MB | |
| 2025-03-28 02:15 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-08-09 08:07 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2024-08-09 08:07 |
Interim Report
半期報告書－第21期(2024/01/01－2024/12/31)
|
Japanese | 262.0 KB | |
| 2024-06-14 08:00 |
Prospectus
有価証券届出書（参照方式）
|
Japanese | 785.1 KB | |
| 2024-05-10 08:08 |
Regulatory News Service
確認書
|
Japanese | 8.8 KB | |
| 2024-05-10 08:07 |
Quarterly Report
四半期報告書－第21期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 213.8 KB | |
| 2024-04-03 02:44 |
Regulatory News Service
臨時報告書
|
Japanese | 24.1 KB | |
| 2024-03-29 01:21 |
Annual Report
有価証券報告書－第20期(2023/01/01－2023/12/31)
|
Japanese | 1.3 MB | |
| 2024-03-29 01:20 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB |
Automate Your Workflow. Get a real-time feed of all Oncolys BioPharma Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Oncolys BioPharma Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
